Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-10-14
|
pubmed:databankReference | |
pubmed:abstractText |
Previously it has been found that binding of the Sp1 transcription factor is not significantly affected by methylation of the CpG dinucleotide within its binding site, 5'-GGGCGG (lower strand, 5'-CCGCCC). Since it has been established that mammalian cells also have the capacity to methylate cytosines (C) at CpNpG sites we examined the effect of methylation of the outer C of the CpCpG on Sp1 binding. We find that methylation of the outer C is inhibitory and in particular methylation of both cytosines (m)Cp(m)CpG inhibits binding by 95%. Furthermore, we have identified endogenous (m)Cp(m)CpG methylation of an Sp1 site in the CpG island promoter of the retinoblastoma (Rb) gene by genomic sequencing. This occurs in a proportion of retinoblastoma tumors which are extensively CpG methylated in the Rb promoter. The results raise the possibility that (m)Cp(m)CpG methylation could have a biological function in preventing Sp1 binding, thereby contributing to the subsequent abnormal methylation of CpG islands often observed in tumor cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0378-1119
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
11
|
pubmed:volume |
195
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
67-71
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9300822-Binding Sites,
pubmed-meshheading:9300822-Cytosine,
pubmed-meshheading:9300822-DNA Methylation,
pubmed-meshheading:9300822-Molecular Sequence Data,
pubmed-meshheading:9300822-Oligonucleotides,
pubmed-meshheading:9300822-Retinoblastoma Protein,
pubmed-meshheading:9300822-Sp1 Transcription Factor
|
pubmed:year |
1997
|
pubmed:articleTitle |
Sp1 binding is inhibited by (m)Cp(m)CpG methylation.
|
pubmed:affiliation |
Kanematsu Laboratories, Royal Prince Alfred Hospital, Camperdown, Australia. clark@pelican.dbe.csiro.au
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|